Navigation Links
Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
Date:2/14/2008

Data Showed AMRIX is Superior to Placebo, Similar Efficacy to Immediate Release Formulation Taken Three Times a Day, and Less Daytime Drowsiness

FRAZER, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced the pooled analysis of two pivotal randomized, placebo-controlled clinical trials showing that AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), a new once-daily extended-release skeletal muscle relaxant, was superior to placebo. AMRIX had similar efficacy to cyclobenzaprine immediate-release (CIR) taken three times a day in alleviating acute muscle spasm associated with lower back and neck pain. In addition, less daytime drowsiness was observed with AMRIX compared to CIR, although such a comparison was not pre-specified in the statistical analysis plan. These results were presented today at the 24th Annual Meeting of the American Academy of Pain Medicine in Orlando, FL.

"Typically, muscle relaxants are taken multiple times a day, which can make it difficult for some of my patients with acute muscle spasm associated with lower back and neck pain to adhere to their treatment regimen," said Arnold J. Weil, MD, of Non-Surgical Orthopaedics in Atlanta, GA, and the lead investigator in these studies. "With data supporting AMRIX as an effective once-daily treatment, health care professionals now have an easy-to-administer treatment option to offer their patients who are suffering from acute muscle spasm."

The data, which were the basis for the U.S. Food and Drug Administration approval of AMRIX, were pooled from two identical 14-day randomized, double-blind, placebo-controlled, multicenter studies, evaluating a total of 504 adults across four study arms (AMRIX 15 mg, AMRIX 30 mg, placebo, and CIR 10 mg three times daily). These participants had moderate-to-severe muscle spasm of cervical or lumbar origin associated with local pain, tenderness, limitation of motion, and restrictions of daily living.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
5. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
9. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
10. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
11. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dr. Kerry Solomon announced that h...aunched his redesigned website at www.DrKerrySolo...g Group. Dr. Solomon is a proven LASIK, lens impl...essionally recognized for his substantial contribu...is a member of Trusted LASIK Surgeons, which scree...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Reportlin...t is available in its catalogue: ,, Emerging C...ynamics and the changing healthcare and regulatory...0165658/Emerging-Clinical-Trial-Locations---Easter...re-and-regulatory-environment.html ,, Over the...
(Date:12/1/2009)..., SHANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shang...ngPharma, a leading China-based Contract Research,... of the 2009 Deloitte,Technology Fast 50 China, ra...tech companies in China. The award is a testament ...owth from 2006 to 2008. , The results of ...
(Date:12/1/2009)... Enterprise level storage is now av...iders without breaking the bank. , ...LC. ( www.pacsdrive.com ), a medical imaging sof...M compatible cloud storage service. The PacsDrive ... providers to securely archive medical imaging in ...
Breaking Biology Technology:Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2
...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:11/30/2009)..., N.J. - The inaugural Global Conference on Syste...2009, in Washington, DC, focuses on the convergenc...f critical importance to society. , The goal...arch activity around targeted complex systems, exa...s topic includes Critical Infrastructure Systems, ...
(Date:11/30/2009)... obstacle to HIV research is the virus,s exquisite...cientists, traditional tools, like the humble lab ...a team of researchers writing in BioMed Central,s ...nious assault on this problem by creating a mouse ...ng infected with HIV. , George Kassiotis, from t...
(Date:11/30/2009)... is a colorless and odorless radioactive gas that ...dium is a product of uranium decay and is found in...s, and groundwater as well as building materials, ...ncentration is expressed as the amount of radiatio...ducts in a liter of air; thus the units are picocu...
Breaking Biology News(10 mins):First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2A reductionist approach to HIV research 2Health Physics Society recommends considering action for indoor radon below current guidelines 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27Safe Ozone Levels May Not Be for Some 52829 1Safe Ozone Levels May Not Be for Some 52829 2
...ts have combined two molecules that occur naturall...es solar energy to split water into hydrogen and o...l of the American Chemical Society. , This molecu...hydrogen gas, providing an alternative to electrol...o its constituent parts. The breakthrough may pave...
...t real-data study of sharks harvested for their va...many as 73 million sharks are killed each year wor...nally by the United Nations, according to a paper ...dition of Ecology Letters. , "The shark fin trade...nto fin auction records and convert from fin sizes...
...ts and medical researchers for the first time have...measures in real time the level of damage to the s...ts suggest that women,s skin ages faster than men,...s Letters, a journal of the Optical Society of Ame... fabric of the deeper layers of the skin, combinin...
Other Biology News:Genetically engineered blood protein can be used to split water into oxygen and hydrogen 2Triple threat: World fin trade may harvest up to 73 million sharks per year 2German researchers develop first non-invasive test to measure skin aging 2German researchers develop first non-invasive test to measure skin aging 3
Rabbit Anti-Methionine Aminopeptidase 2 Polyclonal Antibody, Unconjugated from Abcam
Anti-FKHR, phospho (Thr24) / FKHRL1, phospho (Thr32) Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Ricin communis Monoclonal Antibody, Unconjugated, Clone CP23 from Abcam
Kinase Buffer (10X) from Cell Signaling Technology
Biology Products: